报价延迟最少15分钟:2025/07/20 13:14 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
13.54 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.55/-2.05
|
|
企业价值
1.45B
|
| 资产负债 |
|
每股账面净值
4.08
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 13:14 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia. |
